Britain and America have signed a major bilateral deal that will keep zero levies on UK pharmaceutical products being sold in the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on drugs through the NHS. This pledge ensures that import taxes on these vital products will stay at zero for a timeframe of three years.
This development is in response to recent warnings to significantly raise tariffs on branded drug products, with potential rates discussed reaching double the cost.
"This agreement with the United Kingdom bolsters the international landscape for new treatments and establishes much-needed balance to U.S.–U.K. drug exports," an announcement said.
Trade Impact
Medicines are one of the the United Kingdom's most significant exports to the US, which is easily the primary buyer for leading companies like GSK and AstraZeneca.
Trade data indicate that in the year leading up to last September, the UK exported drugs totaling over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that timeframe.
"This deal protects jobs, increases capital expenditure and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact involves several notable pledges from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to raise overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments exceeded 20%.
Broader Context
The deal takes place against a protracted row between the sector and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that US patients were charged significantly more for the equivalent treatments than patients in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been directed toward US facilities.
One official acknowledged that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
